

Circadian has shifted from being an incubator of early stage technologies to a developer of anti-cancer biologicals...



Circadian Strategy and Directions

Circadian Technologies Limited (ASX:CIR) is a publicly listed biotechnology company based in Melbourne, Australia.

Following the full acquisition of its subsidiary Vegenic Limited in August 2008, Circadian has shifted from being an incubator of early stage technologies and investor in biotechnology to a developer of anti-cancer biologicals based on Vegenic's technology assets.

Circadian is developing biological therapeutics that act by blocking the growth of new blood vessels (angiogenesis) and new lymphatic

vessels (lymphangiogenesis), as novel agents for the treatment of cancer and other diseases.

Circadian owns an extensive IP portfolio related to two vascular endothelial growth factor (VEGF) proteins, VEGF-C and VEGF-D. These rights were acquired primarily from prestigious research institutes, the Ludwig Institute for Cancer Research and the University of Helsinki.


VEGF-C and VEGF-D activate two VEGF receptors (VEGFRs), one of which promotes angiogenesis (VEGFR-2) and the other lymphangiogenesis (VEGFR-3).

Business strategy

Circadian's strategy is to achieve value creation from its IP while minimising risk by developing therapeutics to the point of proof of efficacy in Phase II trials. Depending on opportunities, Circadian will either form partnerships with large pharmaceutical and/or biotechnology companies from early-stage development or for the completion of clinical development.

In addition, Circadian will selectively capitalise on elements of its IP portfolio that lie outside the area of angiogenesis.

Product Pipeline



Circadian has an internal product pipeline of three biotherapeutics targeting key mediators of angiogenesis: VGX-100, the VGX-200 series and VGX-300. The company has licensed the rights of two other drug classes (Trinam® and VEGFR-3 antibodies) to third parties.

Circadian's most advanced program, VGX-100, an antibody targeting VEGF-C; may enter clinical trials as early as 2010.

Circadian Strategy and Directions



Senior Management

Robert Klupacs CEO and Managing Director	CEO, ES Cell International, Head of IP, Amrad
Natalie Korchev CFO and Company Secretary	Antisense Therapeutics
Alex Szabo, Ph.D. Head of Business Development	Bionomics, Beckman-Coulter, Affymetrix
Megan Baldwin, Ph.D. Scientific Affairs Manager	Genentech
Susan Foran Product Development Manager	GSK, Kendle
Richard Chadwick, Ph.D. Intellectual Property Manager	FB Rice, Dow Corning, Unilever



Robert Klupacs, Circadian CEO

Board

Robert Klupacs CEO and Managing Director	CEO, ES Cell International, Head of IP, Amrad
Dominique Fisher Non-Executive Chairman	Pacific Brands, Sky Technologies
Donald Clarke Non-Executive Director	Minter Ellison
Tina McMeckan Non-Executive Director	Deacons, Centre for Eye Research
Carlo Montagner Non-Executive Director	Schering, Sanofi-Aventis
Jonathan Skipper, Ph. D. Non-Executive Director	Ludwig Institute for Cancer Research

Product development advisory group

George Morstyn, M.D.	CMO, Head of Development, Amgen
Errol Malta, Ph.D.	Head, Product Development Team, Amgen
Carlo Montagner	Global Head, Oncology, Schering
Russell Howard, Ph.D.	CEO, Maxygen Inc
Ralph Smalling	Head of Regulatory, Amgen

Partners

Ark Therapeutics Group plc (LSE: AKT)

Ark Therapeutics has a licence of rights to the VEGF-D gene, which forms part of its Trinam[®] product. Under the licence, Circadian will receive royalties on the sales of Trinam and milestone payments upon achievement of product development events. Trinam is a gene therapy product under development to prevent the blocking of blood vessels in kidney dialysis patients who have undergone vascular access graft surgery.

Imclone Systems Inc (NASDAQ: IMCL)

Imclone Systems Inc has a licence of rights to develop antibodies to VEGFR-3 as human therapeutic agents. Imclone currently has a lead antibody in preclinical development. According to the licence agreement, Circadian is entitled to annual licence fees, product milestone payments and royalties on sales.

Contact

Level 1, 10 Wallace Ave
Toorak, VIC 3142, Australia

T +61 3 9826 0399

F +61 3 9824 0083

www.circadian.com.au